OPKO Health, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
OPKO Health, Inc. (OPK) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2019-03-01
- OPKO Health, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-06-30 was 4.82M shares, a 5.71% increase year-over-year.
- OPKO Health, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- OPKO Health, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-06-30 was 4.56M shares.
- OPKO Health, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2015-09-30 was 6.54M shares.
- OPKO Health, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 0.00 shares.
- OPKO Health, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- OPKO Health, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 4.76M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2018-12-31 | 0.00 shares 10-K · filed 2019-03-01 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-03-01 | |||
| 2017-06-30 | 4.82M shares 10-Q · filed 2017-08-08 | 4.72M shares 10-Q · filed 2017-08-08 | ||
| 2016-12-31 | 4.76M shares 10-K · filed 2019-03-01 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-07 | 0.00 shares 10-Q · filed 2016-11-07 | ||
| 2016-06-30 | 4.56M shares 10-Q · filed 2017-08-08 | 4.56M shares 10-Q · filed 2017-08-08 | ||
| 2015-12-31 | 0.00 shares 8-K · filed 2019-01-29 | |||
| 2015-09-30 | 6.54M shares 10-Q · filed 2016-11-07 | 0.00 shares 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-08 | 0.00 shares 10-Q · filed 2016-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |